Last reviewed · How we verify

EC to docetaxel or paclitaxel

RenJi Hospital · Phase 3 active Small molecule

EC to docetaxel or paclitaxel is a Chemotherapy combination regimen Small molecule drug developed by RenJi Hospital. It is currently in Phase 3 development for Breast cancer (likely early-stage or locally advanced, based on typical EC→taxane use). Also known as: Taxol.

EC (epirubicin/cyclophosphamide) followed by docetaxel or paclitaxel is a sequential chemotherapy regimen that damages cancer cell DNA and disrupts microtubule function to inhibit tumor growth.

EC (epirubicin/cyclophosphamide) followed by docetaxel or paclitaxel is a sequential chemotherapy regimen that damages cancer cell DNA and disrupts microtubule function to inhibit tumor growth. Used for Breast cancer (likely early-stage or locally advanced, based on typical EC→taxane use).

At a glance

Generic nameEC to docetaxel or paclitaxel
Also known asTaxol
SponsorRenJi Hospital
Drug classChemotherapy combination regimen
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

This is a multi-agent chemotherapy combination where epirubicin and cyclophosphamide (EC) are administered first as DNA-damaging agents, followed by taxane chemotherapy (docetaxel or paclitaxel) which stabilizes microtubules and prevents cell division. The sequential approach is designed to maximize efficacy while managing cumulative toxicity, commonly used in breast cancer treatment.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about EC to docetaxel or paclitaxel

What is EC to docetaxel or paclitaxel?

EC to docetaxel or paclitaxel is a Chemotherapy combination regimen drug developed by RenJi Hospital, indicated for Breast cancer (likely early-stage or locally advanced, based on typical EC→taxane use).

How does EC to docetaxel or paclitaxel work?

EC (epirubicin/cyclophosphamide) followed by docetaxel or paclitaxel is a sequential chemotherapy regimen that damages cancer cell DNA and disrupts microtubule function to inhibit tumor growth.

What is EC to docetaxel or paclitaxel used for?

EC to docetaxel or paclitaxel is indicated for Breast cancer (likely early-stage or locally advanced, based on typical EC→taxane use).

Who makes EC to docetaxel or paclitaxel?

EC to docetaxel or paclitaxel is developed by RenJi Hospital (see full RenJi Hospital pipeline at /company/renji-hospital).

Is EC to docetaxel or paclitaxel also known as anything else?

EC to docetaxel or paclitaxel is also known as Taxol.

What drug class is EC to docetaxel or paclitaxel in?

EC to docetaxel or paclitaxel belongs to the Chemotherapy combination regimen class. See all Chemotherapy combination regimen drugs at /class/chemotherapy-combination-regimen.

What development phase is EC to docetaxel or paclitaxel in?

EC to docetaxel or paclitaxel is in Phase 3.

What are the side effects of EC to docetaxel or paclitaxel?

Common side effects of EC to docetaxel or paclitaxel include Neutropenia, Anemia, Thrombocytopenia, Nausea/vomiting, Alopecia, Peripheral neuropathy.

Related